154 related articles for article (PubMed ID: 8851601)
21. Sulfa drugs strike more than once.
Patel OG; Mberu EK; Nzila AM; Macreadie IG
Trends Parasitol; 2004 Jan; 20(1):1-3. PubMed ID: 14700578
[No Abstract] [Full Text] [Related]
22. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1997 Oct; 40(22):3694-9. PubMed ID: 9357537
[TBL] [Abstract][Full Text] [Related]
23. Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii.
Kovacs JA; Allegra CJ; Masur H
Exp Parasitol; 1990 Jul; 71(1):60-8. PubMed ID: 2354716
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Gangjee A; Shi J; Queener SF; Barrows LR; Kisliuk RL
J Med Chem; 1993 Oct; 36(22):3437-43. PubMed ID: 8230134
[TBL] [Abstract][Full Text] [Related]
25. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
Rosowsky A; Papoulis AT; Queener SF
J Med Chem; 1998 Mar; 41(6):913-8. PubMed ID: 9526565
[TBL] [Abstract][Full Text] [Related]
26. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of sulfa drugs against recombinant Pneumocystis carinii dihydropteroate synthetase and in vivo.
Hong YL; Hossler P; Bartlett M; Queener S; Smith J; Meshnick S
J Eukaryot Microbiol; 1996; 43(5):40S. PubMed ID: 8822843
[No Abstract] [Full Text] [Related]
28. Dihydropteroate synthase mutations in Pneumocystis jiroveci can affect sulfamethoxazole resistance in a Saccharomyces cerevisiae model.
Iliades P; Meshnick SR; Macreadie IG
Antimicrob Agents Chemother; 2004 Jul; 48(7):2617-23. PubMed ID: 15215118
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and DHFR inhibitory activity of a series of 6-substituted-2,4-diaminothieno[2,3-d]pyrimidines.
Donkor IO; Li H; Queener SF
Eur J Med Chem; 2003 Jun; 38(6):605-11. PubMed ID: 12832132
[TBL] [Abstract][Full Text] [Related]
30. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Ma L; Borio L; Masur H; Kovacs JA
J Infect Dis; 1999 Dec; 180(6):1969-78. PubMed ID: 10558954
[TBL] [Abstract][Full Text] [Related]
31. Toward rational design of species-specific inhibitors of Pneumocystis carinii thymidylate synthase and Toxoplasma gondii dihydrofolate reductase-thymidylate synthase.
Peaslee KA; Anderson AC
J Eukaryot Microbiol; 2001; Suppl():174S-175S. PubMed ID: 11906050
[No Abstract] [Full Text] [Related]
32. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
Gangjee A; Adair O; Queener SF
J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
[TBL] [Abstract][Full Text] [Related]
33. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
34. Drug-resistant Pneumocystis carinii.
Meshnick SR
Lancet; 1999 Oct; 354(9187):1318-9. PubMed ID: 10533856
[No Abstract] [Full Text] [Related]
35. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine.
Rosowsky A; Queener SF; Cody V
Drug Des Discov; 1999 Jul; 16(1):25-40. PubMed ID: 10466054
[TBL] [Abstract][Full Text] [Related]
37. Contribution of dihydropteroate synthase gene typing for Pneumocystis carinii f.sp. hominis epidemiology.
Santos LD; Lacube P; Latouche S; Kac G; Mayaud C; Marteau M; Poirot JL; Maury E; Guillot J; Roux P
J Eukaryot Microbiol; 1999; 46(5):133S-134S. PubMed ID: 10519287
[No Abstract] [Full Text] [Related]
38. Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido[2,3-d]pyrimidines as dihydrofolate reductase inhibitors.
Gangjee A; Adair O; Queener SF
Bioorg Med Chem; 2001 Nov; 9(11):2929-35. PubMed ID: 11597474
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
[TBL] [Abstract][Full Text] [Related]
40. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients.
Armstrong W; Meshnick S; Kazanjian P
Microbes Infect; 2000 Jan; 2(1):61-7. PubMed ID: 10717542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
